Work

Small noncoding RNA TY2 enhances efferocytosis and improves outcomes in a mouse model of sepsis

Year: 2026

Type: article

Abstract: TY2 is a drug based on a natural compound with potent anti-inflammatory effects. TY2 improved outcomes in mice with severe bacterial infection.

Source: JCI Insight

DOI: 10.1172/jci.insight.196153

Authors: Alessandra Ciullo, Xaviar M. Jones, Hiroaki Komuro, Liang Li, Anh Nguyen, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim

Institutions: Cedars-Sinai Medical Center, Cedars-Sinai Smidt Heart Institute

Language: English

Topic: Phagocytosis and Immune Regulation

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,100

Funders: Cedars-Sinai Medical Center, National Institutes of Health, National Heart, Lung, and Blood Institute

Awards: G4863813541, G5051732949, Exosome Therapeutics to Dissect HFpEF Mechanisms, G7490916608, Macrophages as effectors of cell therapy for heart failure, Exosome-based therapeutics for heart failure, G847172856, G9000028755, G9000158338, Mechanisms of cardioprotective Y RNA signaling in macrophages

OpenAlex ID: W7126184776

FWCI:

Cites: 7

Cited by:

Related to: